Perfluoroalkyl Acids in Drinking Water – EPA Method 537

Jul 26, 2016 | Blogs, Environmental / Industrial | 0 comments

The United States Environmental Protection Agency (EPA), under the 1996 Safe Drinking Water Act (SDWA), requires a new list of no more than 30 unregulated contaminants to be monitored by public drinking water systems. Known as the Unregulated Contaminant Monitoring Rule (UCMR), a new list is published every five years. The last rule, UCMR3, was published May 2, 2012, and is the focus of the following application note, “Analysis of Perfluoroalkyl (PFFA) Acids Specified under the UCMR3 Using the QTRAP® 6500 LC-MS/MS system,” which can be found in the Food and Environmental Compendium.

Overview
Using the guidelines laid out by EPA Method 537, “A Determination of Selected Perfluoroalkyl Acids in Drinking Water by Solid Phase Extraction and Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS),” this application note describes the performance of the QTRAP 6500. Within the scope of EPA 537, there are 14 PFAAs. Six are specified under the UCMR3 monitoring list.

Process
Sample preparation and data processing were carried out according to EPA Method 537 without deviation unless specifically noted. The analysis was carried out using the QTRAP 6500 coupled with the Agilent 1260 HPLC with an Eksigent ULC 100 HTC-xt autosampler. Quantitation using MultiQuant ™ 3.0.

Conclusion
The lower the detection, the harder the QTRAP 6500 works for you as it easily meets the UCMR3 reporting limits. See what more it can do when you download the compendium. Download the compendium >

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial